D- mycology Fungi introduction. Fungi are all around us We touch them, we swallow them, we breathe them There are more than 1.5 million fungal species.

D- mycology

Fungi introduction

•Fungi are all around us•We touch them, we swallow them, we breathe them•There are more than 1.5 million fungal species in

nature•Yet only about 100 cause human disease•Most cause superficial infections, some cause allergic

reactions•Few cause invasive infections

Fungal Fast Facts

Why so few invasive infections?

A. Dumb luckB. Most fungi are wimpsC.Some bugs are meaner than

othersD.Some people are meaner than

othersE. A little of all of these

Host/Pathogen Balance:Normal Circumstances

Host Factors

Anatomical barriers

Adaptive immunity

Innate defenses

Virulence

Fungal Burden

Fungal Factors

Protection Infection

Why so few Invasive Infections?

Fungi as Primary Pathogens in Healthy Individuals

Conditions that disrupt immune defenses

•Neutropenia•Immunosuppression

Fungi as Opportunists

What are the major fungi I need to worry about?

A. CoccidiomycosisB. HistoplasmosisC.CandidaD.AspergillusE. CryptococcusF. Zygomycetes

Mortality Due to Invasive Mycoses

PathogenOverall

Mortality

Candida spp 40%

Aspergillus spp 62%

Other Invasive moulds (Fusarium spp.,

Zygomycetes)~80%

Scedosporium spp. 100%

*Adults hospitalized in the US; †Hospitalized patients with IA; ‡HSCT recipients.1. Pappas PG, et al. Clin Infect Dis. 2003;37:634-643; 2. Wisplinghoff H, et al. Clin Infect Dis. 2004;39:309-317; 3. Perfect J, et al. Clin Infect Dis. 2001;33:1824-1833; 4. Marr KA, et al. Clin Infect Dis. 2002;34:909-917.

Risk for Invasive Candidiasis Risk for Invasive Candidiasis Is a ContinuumIs a Continuum

High-risk patients

• Surgery

• Leukopenia

• Burns• Premature infants

Exposures

• ICU >7 days

• CVCs

• Antibiotics

• TPN• Colonization

If candidemia develops…• ~40% die

• ~60% survive

CVCs=central venous catheters; TPN=total parenteral nutrition.Rex JH, et al. Adv Intern Med. 1998;43:321-369; Pappas PG, et al. Clin Infect Dis. 2003;37:634-643.

Case 1Patient with Acute Leukemia

• 36 yo woman with AML in CR1 given HDAC to mobilize for stem cell collection & consolidation

• Discharged on ciprofloxacin, no fluconazole• Day 15 admitted for sepsis; blood cultures grew ESBL

E. coli (sensitive only to imipenem, meropenem, gentamycin)

• She received imipenem + vancomycin• Fever persists• CT scan done 7 days later

What does this patient have?

• Bacterial abscesses• Spread of leukemia to

liver• Hemangiomas• Hepatic candidiasis

Case 2

• 43 years old male, GSW to abdomen– Arrives in shock– 1.5 liter combined blood loss from trauma and surgery– Sigmoid colon injury with fecal contamination– Renal laceration– Hypothermia and acidosis

Course

• Venous and urinary catheters placed, intubated

• Cefoxitin 1 gram IV en route to OR

• Exploratory laparotomy

• Left nephrectomy

• Sigmoid colectomy and colostomy

Post-Operative Course

• Fever persists, now day 5• Awake and lethargic• Abdominal exam: typical post-op

What tests would you order?

•CT

•Check catheter

•Chest x Ray

•Urine/blood culture

•Percutaneous aspirate

Findings

•Aspirate grows E. coli

•Antibiotics modified

•Fever persists

Evaluate for Fungus?

•He has the risk factors

•He has other causes for fever

•Treat “presumptively” for fungus? (or) Wait for positive fungus culture?

•Which drug if you treat?

Laboratory Results

• Negative blood cultures• Urine culture positive for Candida

– C. albicans identified by PNA-FISH

• You examine his eyes

What Is the Diagnosis?

Key clinical features of Candida infections

• Invasive Candida infections rarely are the first infection, more commonly “superinfections”

• They are opportunists– Breach in host barriers by catheters, trauma, surgery– Impaired immune defenses– Antimicrobial agents

• Bacterial flora suppressed by antibiotics• Certain fungi are suppressed by specific antifungal agents

• Risk for infection determined by interplay of bug, host, and environmental pressures– Microbe’s virulence factors– Impairment of host defenses– Selection of resistant bugs by antimicrobial agents

used• Fever often the only clinical manifestation

CandidiasisSpectrum of Infection

Images courtesy of Kenneth V. Rolston, MD, and John R. Wingard, MD.Images courtesy of Kenneth V. Rolston, MD, and John R. Wingard, MD.Walsh et al. Walsh et al. Infect Dis Clin North AmInfect Dis Clin North Am. 1996;10:365-400.. 1996;10:365-400.

Cutaneous fungemia

Chorioretinitis

Disseminated

Mucosal

Who gets Candidemia?

2000 2001 2002

Nguyen, unpublished data from Shands at UF

Systemic Fungal InfectionsMANAGEMENT

Remove focus of infection

Remove/decrease immunosuppression

Restore Immune Function

Begin antifungal therapy - EARLY!

Delaying Antifungal Therapy Until Blood Cultures are Positive: A Risk for Hospital Mortality

Morrell M, et al. Antimicrob Agents Chemother 2005;49:3640-5

• 157 patients with candidemia

• Initiation of antifungal therapy after blood culture

<12 hours: 9 (5.7%)12 to 24 hours: 10 (6.4%)24 to 48 hours: 86 (54.8%)> 48 hours: 52 (33.1%)

• Independent determinants of hospital mortality

APACHE II score (one-point increments) (p <0.001)

Prior antibiotics (p = 0.028)Administration of antifungal therapy 12

hours after the first positive blood culture (p = 0.018)

(n=9) (n=10) (n=86) (n=52)

Catheters & Candidemia

•Non-neutropenic–#1 source!

•Cancer patients–Tunneled lines are less often sources–The gut is probably a frequent source in neutropenic patients with mucositis

• Consider changing lines. May help some pts.

Start Rx

What are the targets for antifungal therapy?

Cell membraneFungi use principally ergosterol instead of cholesterol

Cell WallUnlike mammalian cells, fungi have a cell wall

DNA SynthesisSome compounds may be selectively activated by fungi, arresting DNA synthesis.

Atlas of fungal Infections, Richard Diamond Ed. 1999Introduction to Medical Mycology. Merck and Co. 2001

Cell Membrane Active Antifungals

Cell membrane • Polyene antibiotics - Amphotericin B, lipid formulations - Nystatin (topical)

• Azole antifungals - Ketoconazole - Itraconazole - Fluconazole - Voriconazole - Posaconazole - Miconazole, clotrimazole (and other topicals)

Antifungals acting on fungal DNA synthesis

Cell membrane • Polyene antibiotics • Azole antifungals

DNA/RNA synthesis • Pyrimidine analogues - Flucytosine

Cell wall • Echinocandins

Cell Wall Active Antifungals

Cell membrane • Polyene antibiotics • Azole antifungals

DNA/RNA synthesis • Pyrimidine analogues - Flucytosine

Cell wall • Echinocandins -Caspofungin -Micafungin -Anidulafungin

Atlas of fungal Infections, Richard Diamond Ed. 1999Introduction to Medical Mycology. Merck and Co. 2001

Treatment Guidelines for Candidemia:Infectious Disease Society of America 20041,2

Con

ditio

nP

rimar

yth

erap

yA

ltern

ativ

e th

erap

y Amphotericin B +fluconazole 4–7 days then fluconazole

Fluconazole or caspofungin

Fluconazole

Non-neutropenic adults

Chronic disseminated candidiasis

Neutropenic adults

Amphotericin Bor fluconazoleor caspofungin

Amphotericin B (conventional or liposomal)

Amphotericin B (conventional or liposomal) orcaspofungin

1. Pappas PG et al. Clin Infect Dis. 2004;38:161–189.2. Perfect JR. Oncology. 2004;18(suppl):15–22.

Aspergillus• Moulds• True hyphae• Exogenous, airborne

• Soil• Water / storage tanks in hospitals

etc• Food• Compost and decaying vegetation• Fire proofing materials• Bedding, pillows• Ventilation and air conditioning

systems• Computer fans

• Portal of entry: nasal passages, respiratory tract

• Potential for hospital outbreaks

Patterson/ASPERFILE Study Group, MEDICINE, 2000.Patterson/ASPERFILE Study Group, MEDICINE, 2000.

595 Patients595 Patients

Hematologic29%

BMT/Allo25%

Solid Solid TransplantTransplant

9%9%

AIDS8%

Other Other ImmuneImmune

6%6%

Pulm9%

Other5%

None2%

BMT/Auto7%

Invasive AspergillosisUnderlying Diseases

Acute Invasive Aspergillosis

Sequential high-resolution CTs in 25 patients with neutropenia and IPA at diagnosis: median number of lesions=2, bilateral in 48%

Baseline: haloBaseline: halo Day 4: ↑size, ↓haloDay 4: ↑size, ↓halo Day 7: air crescentDay 7: air crescent

Halo transitory: <5 days; increased volume for 1 week → stabilization → air crescentIPA=invasive pulmonary aspergillosis.IPA=invasive pulmonary aspergillosis.

Slide courtesy of Kieren A. Marr, MD.

Caillot et al. J Clin Oncol. 2001:19:253-259..

Invasive AspergillosisOther Clinical Presentations

Images courtesy of Kenneth V. Rolston, MD..Stevens et al. Clin Infect Dis. 2000;36:696-709;

Walsh et al. Infect Dis Clin North Am. 1996;10:365-400..

B. CerebritisA. Sino-orbital disease C. Cutaneous infection

Case 3Patient with acute leukemia

• 51 yo man with AML• Cytogenetics: intermediate risk

category• Induced with 3 + 7 (Idarubicin +

cytarabine)• Pneumonia at time of count recovery• Bone marrow shows pt to be in CR1

Case 3Radiography

Case 3Bronchoscopy

Culture: Aspergillus fumigatus

Treatment principles

• Reduce immunosuppresion, restore immunity if possible

• Start antifungal therapy promptly– Polyenes– Mould-active azoles– Echinocandins

• Consider surgical resection of infarcted tissue in certain situations

IDSA Aspergillus Treatment Guidelines for Primary Therapy of Invasive Aspergillosis

• Preferred therapy:•Voriconazole is recommended for the primary treatment of invasive aspergillosis in most patients

•Alternative Agents:•Liposomal therapy could be considered as alternative primary therapy in some patients (AI).

Early Diagnosis Can Be Helpful

P<0.001

Greene RE, et al. Clin Infect Dis 2007;44:373-9

Zygomycetes

•Resistant to voriconazole•Increased infections in

setting of voriconazole prophylaxis1,2

•Frequent cause of breakthrough infection in patients receiving voriconazole1,2

•Increased incidence of Zygo infections at MDACC3

–Case-control study of Zygo (n=27) vs IA (n=54) patients

•Risks among leukemia patients are diabetes, malnutrition, and voriconazole prophylaxis

1. Marty PM et al. N Eng J Med. 2004;350:950.2. Imhof A et al. Clin Infect Dis. 2004;39:743.3. Kontoyiannis et al. J Infect Dis. 2005;191:1350.

0.70.60.50.40.30.20.10.0In

cide

nce

of I

A p

er

1,00

0 P

atie

nt-D

ays

2000 2001 2002 20030.00

0.210.180.150.120.090.060.03

Inciden

ce of Z

ygom

ycosispe

r 1,000

Patien

t-Days

Year

AspergillusZygomycetes

Amphotericin BVoriconazole

0

1000

800

600

400

200

1800

1600

1400

1200

2000

To

tal G

ram

s D

isp

ense

d

to H

emat

olo

gica

lM

alig

nan

cy a

nd

BM

T S

ervi

ces

Sep

-02

Oct

-02

Nov

-02

Dec

-02

Jan-

03F

eb-0

3M

ar-0

3A

pr-0

3M

ay-0

3Ju

n-03

Jul-0

3A

ug-0

3S

ep-0

3O

ct-0

3N

ov-0

3D

ec-0

3Ja

n-04

Feb

-04

Mar

-04

Apr

-04

Summary (1)

• Invasive fungal infections occur as a result of interplay between bug, host, and antimicrobial pressures– Organism’s inherent virulence– Impaired host defenses tips balance in organism’s favor– Ecological advantage offered by suppression of other microbes in

the host environment

• Invasive fungal infections are mostly opportunistic– Take advantage of breach in host defense

Summary (2)

• Candida is the most common invasive fungal pathogen in hospitalized patients– Part of endogenous flora– Portal of entry: skin, mucosa– Fever is often the only manifestation– Usually disseminates via bloodstream– Early recognition and treatment is key to successful

treatment• Aspergillus is much less common but even

more deadly– Airborne– Portal of entry: nasal passages, respiratory tract– Pneumonia, sinusitis usual presentation